HOLX Hologic
FY2025 10-K
Hologic (HOLX) filed its fiscal year 2025 10-K annual report with the SEC on Nov 18, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Developer and supplier of diagnostics, medical imaging, and surgical products focused on women’s health across four segments: Diagnostics, Breast Health, GYN Surgical, Skeletal Health
- • New digital cytology platform Genius Digital Diagnostics System cleared by FDA in Jan 2024, combines AI with volumetric imaging for cervical cancer detection
Management Discussion & Analysis
- • Cash and cash equivalents $1,959.5M, down $200.7M YoY due to stock repurchases, Gynesonics acquisition ($321.5M), capex $137M, strategic investments $35M
- • Operating cash flow $1,057.1M driven by net income $565.7M and $299.8M depreciation, offset by $141.6M deferred tax decrease
Risk Factors
- • Legal risk from ongoing governmental and regulatory investigations affecting potential litigation costs
- • Macroeconomic exposure to increased Weighted Average Cost of Capital (WACC) impacting goodwill fair value, goodwill $3.6B at risk if markets deteriorate
Financial SummaryXBRL
Revenue
$4.1B
Net Income
$566M
Gross Margin
51.6%
Operating Margin
17.4%
Net Margin
13.8%
ROE
11.2%
Total Assets
$9.0B
EPS (Diluted)
$2.49
Operating Cash Flow
$1.1B
Source: XBRL data from Hologic FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Hologic
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.